AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01583504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High volume saline injection
Description: After steroid and local anaesthetic has been delivered, a bolus of normal saline will also be infused into the space between Kager's fat pad and the achilles tendon through the same needle, using ultrasound guidance and sterile technique. At least 14mls will be given but up to 40mls could be used. Saline will be injected until the injector determines that the appearance of neovascularisation on ultrasound has disappeared.
Study NCT01583504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise programme
Description: a bandage will be placed on the ankle for 48 hours and instructions given to rest the ankle. The patient will be verbally shown a programme of exercises to be done over the next 6 weeks to stretch the tendon and steadily build up load bearing on it. The exercises are also clearly shown on a leaflet which the patient takes home.
Study NCT01583504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise programme
Description: a bandage will be placed on the ankle for 48 hours and instructions given to rest the ankle. The patient will be verbally shown a programme of exercises to be done over the next 6 weeks to stretch the tendon and steadily build up load bearing on it. The exercises are also clearly shown on a leaflet which the patient takes home.
Study NCT03002298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DMD gesture task
Description: Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
Study NCT03002298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DMD button-press task
Description: Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
Study NCT03002298 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group gesture task
Description: Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
Study NCT03002298 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group button-press task
Description: Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
Study NCT01391637 — intervention group
Intervention type: BIOLOGICAL
Intervention: HuCNS-SC transplant in the lead-in phase
Description: Long-term safety follow-up study
Study NCT00905320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metallic Fasteners and Sutures
Description: Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners and sutures.
Study NCT00905320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metallic Fasteners Alone
Description: Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners alone.
Study NCT00445835 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arterial doppler for screening asymptomatic and significant extracoronary arterial stenoses in all arterial beds
Description: A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
Study NCT00445835 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conservative arm
Description: Conservative medical approach
Study NCT02956837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3003891A) formulation 1
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
Study NCT02956837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3003891A) formulation 2
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
Study NCT02956837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3003891A) formulation 3
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
Study NCT02956837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Formulation buffer S9b)
Description: A single dose of placebo is administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
Study NCT00269321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic Manual treatment + home exercise (procedure+behavior)
Description: The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation, mobilization and flexion-distraction therapy with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
Study NCT00269321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supervised rehabilitative exercise+home exercise
Description: The rehabilitative exercise program will consist of 20, 1-hour sessions. It is a modification of exercise protocols used in previous studies by the investigators and incorporates recommendations of leading rehabilitative exercise specialists.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
Study NCT00269321 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
Study NCT00867984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Torsion optimized
Description: Torsion optimized VV timing plus AV optimization (VTI)
Study NCT03172377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lengthening adalimumab dosing interval
Description: Lengthening adalimumab dosing interval from 2 weeks to 3 weeks and -later- to 4 weeks.
Study NCT00003832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromodeoxyuridine
Description: Given IV
Study NCT00867984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: AV optimization (VTI) only
Study NCT01727505 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sequence A: Conventional-Volume Guarantee
Description: This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence A, the infant will undergo a 24-hour period of conventional mechanical ventilation followed by a 24 hour period of volume guarantee ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study.
Study NCT01727505 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sequence B: Volume Guarantee-Conventional
Description: This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence B, the infant will undergo a 24-hour period of volume guarantee ventilation followed by a 24 hour period of conventional mechanical ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study.
Study NCT00990444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin in Dextran Matrix
Description: Fixed dose capsule with 100 IU of insulin in dextran matrix. Investigational drug or placebo are administered in conjunction with food intake on a background of metformin.
Study NCT00990444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin in Dextran Matrix
Description: Fixed dose capsule with 100 IU of insulin in dextran matrix. Investigational drug or placebo are administered in conjunction with food intake on a background of metformin.
Study NCT05037643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: Transjugular Intrahepatic Portosystemic Shunt is performed to prevent / treat symptomatic portal hypertension
Study NCT02892643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic proximal gastrectomy
Description: Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
Study NCT02892643 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic total gastrectomy
Description: Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
Study NCT04001647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylcholine
Description: Endothelium-dependent vasodilation will be determined via graded intra-arterial infusions of acetylcholine (ACh). Doses of 1, 4, 8, and 16 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
Study NCT04001647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Endothelium-dependent vasodilation will be determined via graded intra-arterial infusions of acetylcholine (ACh). Doses of 1, 4, 8, and 16 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
Study NCT04001647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Nitroprusside
Description: Endothelium-independent vasodilation will be determined via graded intra-arterial infusions of sodium nitroprusside (SNP). Doses of 0.25, 0.5, 1, and 2 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
Study NCT04001647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: Endothelium-independent vasodilation will be determined via graded intra-arterial infusions of sodium nitroprusside (SNP). Doses of 0.25, 0.5, 1, and 2 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
Study NCT04001647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic Acid
Description: The influence of oxidative stress on arterial stiffness and vasodilation will be assessed by using intravenous ascorbic acid (AA). A single supra-physiological dose of 0.06 g/kg fat-free mass (FFM) will be infused over 20 min followed by a drip infusion of 0.02 g/kg FFM administered over 60 min.
Study NCT04001647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: The influence of oxidative stress on arterial stiffness and vasodilation will be assessed by using intravenous ascorbic acid (AA). A single supra-physiological dose of 0.06 g/kg fat-free mass (FFM) will be infused over 20 min followed by a drip infusion of 0.02 g/kg FFM administered over 60 min.
Study NCT03842540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SpeakOut
Description: SpeakOut aims to increase social communication about contraception between adolescent IUD and implant users and their peers. SpeakOut has four components:~1. Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~2. Digital materials for recipients to keep and/or share with friends.~3. Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~4. Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut.
Study NCT03842540 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PartyWise
Description: The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. Staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
Study NCT01424813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDPI
Description: Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Study NCT01424813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI
Description: Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Study NCT00786552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed + paclitaxel
Description: Pemetrexed 500 mg/m² i.v. over 10 minutes on day 8 Paclitaxel 90 mg/m² i.v. over 60 minutes on day1 and 8
Study NCT01770795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM/Gemcitabine
Study NCT02278484 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: XprESS device and PathAssist confirmation tools
Study NCT00513708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation Enhancement Therapy (MET)
Description: Participants assigned to this arm will receive a 60-minute MET intervention in addition to usual care while hospitalized for detoxification.
Study NCT00513708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Twelve Step Facilitation (P-TSF)
Description: In addition to usual care while hospitalized for detoxification, participants assigned to this arm will receive a 60-minute visit by peers who are recovering from alcoholism and who are active in 12-step oriented self-help programs.
Study NCT00003832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo surgery
Study NCT00003832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02425462 — intervention group
Intervention type: DRUG
Intervention: Dienogest (Visanne, BAY86-5258)
Description: Dienogest 2mg daily Oral dose
Study NCT00385827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Description: Mitoxantrone 12 mg/m\^2 intravenously as a 30 minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m\^2)
Study NCT00385827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone 12 mg/m\^2 intravenously as a 30 minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m\^2)
Study NCT04283890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab and nivolumab
Description: The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
Study NCT04283890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab and nivolumab
Description: The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
Study NCT04283890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan chemosaturation via percutaneous hepatic perfusion
Description: The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
Study NCT04283890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan chemosaturation via percutaneous hepatic perfusion
Description: The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
Study NCT02741453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice
Study NCT02741453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral IJ Ultrasound Scanning
Study NCT01701102 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine (24 mg) plus fentanyl
Description: Mepivacaine (24 mg) and fentanyl (10 µg)
Study NCT01701102 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine (27 mg) plus fentanyl
Description: Mepivacaine (27 mg) and fentanyl (10 µg)
Study NCT01701102 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine (30 mg) plus fentanyl
Description: Mepivacaine (30 mg) and fentanyl (10 µg)
Study NCT01701102 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: Mepivacaine 37.5 mg
Study NCT02391142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 0.5% lidocaine 5ml epidural injection every 2 hours per day or 0.2% ropivacaine 5ml epidural injection every 4 hours per day, last for 4weeks
Study NCT00250744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant vs. Gabapentin
Description: Gabapentin 300mg PO QHS day -2; 300mg PO BID day -1; 300mg PO TID days 0 through +5.
Study NCT00250744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant vs. Gabapentin
Description: Aprepitant 125mg PO 60 minutes prior to chemotherapy on day 0; 80 mg PO QAM on days +1 and +2.
Study NCT02920970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon A
Description: contact lens
Study NCT02920970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A
Description: contact lens
Study NCT00788970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure adjuvant therapy
Description: Acupressure provided in 40-minute sessions, twice a week for 4 weeks. For placebo acupressure, different meridian points will be used.
Study NCT00788970 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acupressure adjuvant therapy
Description: Acupressure provided in 40-minute sessions, twice a week for 4 weeks. For placebo acupressure, different meridian points will be used.
Study NCT01969851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Oral intake twice daily of tablet (100 mg or 50 mg) or syrup formulation (10 mg/ml).~Total daily dose will be titrated over a period of 6 weeks with starting dose of 100 mg/day or 2 mg/kg/day up to doses not exceeding 600 mg/day or 12 mg/kg/day tablet or syrup, respectively. Followed by a 12 week maintenance period with stable dosing of at least 200 mg/day or 4 mg/kg/day tablet or syrup, respectively.
Study NCT02269423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.
Study NCT02269423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline placebo.
Study NCT02269423 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline placebo.
Study NCT00208559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ziprasidone
Description: Ziprasidone 40mg to 60mg per day, individually titrated
Study NCT00391703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electrostimulation programme: using a cycloergometer
Description: Quadriceps electrostimulation programme performed prior to an endurance retraining program using a cycloergometer, for 6 weeks, 60 to 90 minutes by session, 5 to 6 sessions per week
Study NCT00391703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual sport activity
Description: Usual sport activity performed prior to an endurance retraining program using a cycloergometer
Study NCT02221557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: easy-graft (beta-Tricalcium Phosphate)
Study NCT03470259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV adminstration of EMI-137
Description: Intravenous administration of the fluorescent tracer EMI-137 approximately two hours before incision. Thereafter will be an observational period of an hour.